Instrument Inactif

Autres langues Entasis Therapeutics Holdings Inc.

Actions

ETTX

US2936141033

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022	19/10/22
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from S&P TMI Index	13/07/22
Innoviva Acquires Remaining Stake in Entasis Therapeutics	11/07/22
Entasis Therapeutics : Termination of a Material Definitive Agreement - Form 8-K	11/07/22
ENTASIS THERAPEUTICS HOLDINGS INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	11/07/22
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index	11/07/22
Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.	11/07/22
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell 3000E Value Index	24/06/22
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index	24/06/22
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference	10/06/22
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference	09/06/22
Entasis Therapeutics : Innoviva to Acquire Entasis Therapeutics - Form 8-K	23/05/22
ENTASIS THERAPEUTICS HOLDINGS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	23/05/22
ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX	23/05/22
Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell	23/05/22
Innoviva to Acquire Entasis Therapeutics	23/05/22
Innoviva to Acquire Entasis Therapeutics	23/05/22
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference	18/05/22
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference	17/05/22
Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference	17/05/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Entasis Therapeutics Holdings Inc.

Actions

ETTX

US2936141033

Autres langues

Filtres